Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Olutasidenib met of zonder azacitidine bij IDH1-gemuteerde AML en MDS
feb 2023 | Leukemie, MDS